{"id":"nsai-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Increased cardiovascular risk (with chronic use)"},{"rate":null,"effect":"Renal impairment (with chronic use)"}]},"_chembl":{"chemblId":"CHEMBL7257","moleculeType":"Small molecule","molecularWeight":"218.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NSAIs (nonsteroidal anti-inflammatory drugs) work by inhibiting cyclooxygenase (COX) enzymes, which reduces the production of prostaglandins and other inflammatory mediators. This mechanism decreases inflammation, pain, and fever across various conditions. The exact formulation and specific COX selectivity depend on the particular NSAI compound being referenced.","oneSentence":"NSAI treatment inhibits nonsteroidal anti-inflammatory agents to reduce inflammation and associated symptoms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:57:52.855Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory conditions and pain management"},{"name":"Potentially fever reduction in infectious diseases (context-dependent on LSHTM research focus)"}]},"trialDetails":[{"nctId":"NCT02246621","phase":"PHASE3","title":"A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-11-06","conditions":"Breast Cancer","enrollment":493},{"nctId":"NCT03671330","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-29","conditions":"Breast Cancer","enrollment":327},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT03425838","phase":"PHASE3","title":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2017-11-09","conditions":"Breast Neoplasm Female","enrollment":1050},{"nctId":"NCT07072013","phase":"","title":"An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-09-08","conditions":"Breast Cancer","enrollment":1937},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT06375707","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-09","conditions":"Advanced Breast Cancer","enrollment":144},{"nctId":"NCT02304783","phase":"PHASE3","title":"Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2014-01","conditions":"Renal Colic","enrollment":1400},{"nctId":"NCT02278120","phase":"PHASE3","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-20","conditions":"Advanced Metastatic Breast Cancer","enrollment":672},{"nctId":"NCT04714619","phase":"PHASE2","title":"CB-103 Plus NSAI In Luminal Advanced Breast Cancer","status":"TERMINATED","sponsor":"MedSIR","startDate":"2021-05-06","conditions":"Advanced Breast Cancer","enrollment":2},{"nctId":"NCT04707196","phase":"PHASE4","title":"A Study of Abemaciclib in Indian Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-02-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":200},{"nctId":"NCT05722782","phase":"PHASE2","title":"Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics","status":"RECRUITING","sponsor":"University of Monastir","startDate":"2023-07-01","conditions":"Renal Colic","enrollment":500},{"nctId":"NCT02028364","phase":"PHASE2","title":"Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2014-01-12","conditions":"Breast Cancer","enrollment":55},{"nctId":"NCT02753686","phase":"","title":"Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-03-15","conditions":"HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer","enrollment":440},{"nctId":"NCT01791985","phase":"PHASE1, PHASE2","title":"AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-07","conditions":"Breast Cancer","enrollment":52},{"nctId":"NCT04183556","phase":"NA","title":"The Effect of Turmeric on New Onset Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Batman Training and Research Hospital","startDate":"2019-11-15","conditions":"Primary Dysmenorrhea","enrollment":90},{"nctId":"NCT02156596","phase":"PHASE1","title":"IV NSAI Versus Nebulized Morphine Analgesia for First-line Renal Colic","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2013-02","conditions":"Renal Colic","enrollment":100},{"nctId":"NCT00863655","phase":"PHASE3","title":"Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06-03","conditions":"Breast Cancer","enrollment":724},{"nctId":"NCT02527603","phase":"NA","title":"Spaso Versus Self-assisted Maneuver for Anterior Shoulder Dislocation","status":"COMPLETED","sponsor":"Corporacion Parc Tauli","startDate":"2015-08","conditions":"Shoulder Dislocation","enrollment":60},{"nctId":"NCT01626222","phase":"PHASE3","title":"4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Metastatic Breast Cancer","enrollment":301},{"nctId":"NCT02404051","phase":"PHASE3","title":"Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2015-12","conditions":"Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":745},{"nctId":"NCT01816334","phase":"PHASE4","title":"Safety and Efficacy of Nonsteroidal Antiinflammatory (NSAI)Drug and Glucocorticoids in Acute Sciatica","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2013-01","conditions":"Sciatica","enrollment":50},{"nctId":"NCT01452997","phase":"PHASE4","title":"Evaluation of Anti-inflammatories in the Reduction of Bite Reactions","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2012-11","conditions":"Mosquito Bite","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":101,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fenbid gel"],"phase":"marketed","status":"active","brandName":"NSAI treatment","genericName":"NSAI treatment","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NSAI treatment inhibits nonsteroidal anti-inflammatory agents to reduce inflammation and associated pain. Used for Inflammatory conditions (specific indication unclear from available information).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}